FDA Grants Priority Review Status To Velcade – The U.S. Food and Drug Administration (FDA) granted priority review to the supplemental new drug application for Velcade (bortezomib) from Millennium: The Takeda Oncology Company. The supplemental new drug application includes long-term overall survival data from the Phase 3 Vista trial, which examined treatment with Velcade in patients with previously untreated multiple myeloma. Applications granted priority review are approved by the FDA within six months instead of ten. For more information, please see the Millennium press release.

Celgene To Benefit From Increased Use Of Revlimid – Analysts believe that Celgene's stock may recover by the end of this year due to more doctors treating patients with Revlimid (lenalidomide). Revlimid is becoming more accepted as a maintenance treatment for multiple myeloma, lymphoma, and leukemia. Also, Celgene will report on a new clinical trial in December, which may raise sales. For more information, please see the Forbes article.

MMRF Chicago Marathon – On October 11 the Multiple Myeloma Research Foundation (MMRF) team will be taking part in the Bank of America Chicago Marathon. The MMRF is seeking contributions for its runners, which will go towards helping to fund multiple myeloma research. For more information, please visit the MMRF Web site.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.